New A.L.S. Treatment Lacks Evidence of Benefit, F.D.A. Panel Finds
With a 6-4 vote, the group of independent advisers to the agency narrowly concluded that results from another clinical trial are needed to assess whether the therapy, called AMX0035, can help patients.
View original article
Contributor: Pam Belluck
